iiinova — where your digital self keeps evolving

Reposted by Tumor Board Tuesday

Mike Pishvaian @mpishvaian.bsky.social · 22/10/2025

#tumorboardtuesday 🤔Hmmm....much more rapid disease progression on the CDK4/6🚫+AI - does this portend for a worse prognosis in subsequent lines of therapy❓

011

Reposted by Tumor Board Tuesday

Mike Pishvaian @mpishvaian.bsky.social · 22/10/2025

#tumorboardtuesday Any subtle differences in outcomes based on the specific mutation identified AKT vs. PTEN vs. PIK3CA❓

011

Tumor Board Tuesday @tumorboardtuesday.bsky.social · 21/10/2025

#TumorBoardTuesday 📢Join us Tuesday, 10-21-25 at 8PM ET as @drgattimays.bsky.social & @KennaKoehler 🗣️ Tx options after CDK4/6⛔️: What to consider in the 2nd line for HR+/HER2– mBC❓ RT and bring others into the discussion‼️

111

Reposted by Tumor Board Tuesday

Margaret Gatti-Mays, MD MPH @drgattimays.bsky.social · 21/10/2025

Tune in tomorrow 10/21/25 at 8pm EST for discussion about the ever changing landscape of 2L metastatic ER+ breast cancer #TBT #BCSM @tumorboardtuesday.bsky.social @osuwexmed.bsky.social #BreastCancer

011

Reposted by Tumor Board Tuesday

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

24/31 #TumorBoardTuesday 🏫Mini Tutorial 21🏫 Pooled analysis of CT041 in met panc (NCT03874897, NCT04581473) 24 pts with advanced panc ORR 16.7%, DCR 70.8% mPFS 3.3 mos, mOS 10 mos mDOR 9.5 mos, DOR 50% at 12 mos AEs: CRS, GI doi.org/10.1200/JCO.23.02314

142

Reposted by Tumor Board Tuesday

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

25/31 #TumorBoardTuesday 🏫Mini Tutorial 22🏫 2) Phase 1b/2, CT041 in CLDN18.2+ adv gastric or panc (ELIMYN18.2, NCT04404595) 19 patients: 7 gastric/GEJ cancer, 12 pancreatic cancer doi.org/10.1200/JCO.2024.42.3_suppl.356

143

Reposted by Tumor Board Tuesday

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

26/31 #TumorBoardTuesday 🏫Mini Tutorial 23🏫 58% panc pts had ≥3 prior lines PC: ORR 16.7%, mDOR 3.4 mos, CBR 33.3% At dose level 3, 2/5 PR in panc pts CRS mostly grade 1-2, 2 cases grade 3 ICANS grade 1 in 2 pts

153

Reposted by Tumor Board Tuesday

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

27/31 #TumorBoardTuesday Back to our case🔎 Enrolled in CD3 x CLDN18.2 BiTE trial At 1 month, SD by CT but rising CA19-9 (206 -> 791)

143

Reposted by Tumor Board Tuesday

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

28/31 #TumorBoardTuesday 🏫Mini Tutorial 24🏫 How about CLDN18.2 BiTE+X combos? 1) BiTE+chemo Chemo increases immunogenicity, depletes immunosuppressive Tregs (CD3-targeting BiTEs recruit polyclonal T cells, including Tregs) NCT05365581: ASP2138 (CD3 x CLDN18.2) ± chemo

152

Reposted by Tumor Board Tuesday

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

29/31 #TumorBoardTuesday 🏫Mini Tutorial 25🏫 2) BiTE+ICI BiTEs -> inhibitory checkpoints upregulated KPC orthotopic model: CLDN18.2 x CD3 BiTE + αPD1 -> decreased tumor growth compared to BiTE or αPD1 alone doi.org/10.1053/j.gastro.2023.06.037

142

Reposted by Tumor Board Tuesday

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

30/31 #TumorBoardTuesday 🏫Mini Tutorial 26🏫 3) BiTE+OV Oncolytic virus -> tumor lysis -> T cell response SQ model of KPC w/ human CLDN18.2 in CD3ε humanized mice: OV-BiTE improved tumor control and survival compared to OV-GFP or PBS ctrl doi.org/10.1016/j.omto.2023.08.011

142

Reposted by Tumor Board Tuesday

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

31/31 #TumorBoardTuesday 🏫Mini Tutorial 27🏫 Choice of CLDN18.2 BiTE vs CAR-T? BiTE: off the shelf, continuous therapy CAR-T: autologous (takes time), one infusion doi.org/10.1186/s13045-021-01067-5

132

Reposted by Tumor Board Tuesday

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

23/31 #TumorBoardTuesday 🏫Mini Tutorial 20🏫 96.9% CRS, all grade 1-2 8% gastric mucosal injury, 1 pt w/ grade 3 No DLTs, treatment related deaths, ICANS

133

Reposted by Tumor Board Tuesday

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

22/31 #TumorBoardTuesday 🏫Mini Tutorial 19🏫 ORR 38.8%, DCR 91.8%, mDOR 6.4 mos Among 10 pts with PDAC: 2 PR, 7 SD, 1 PD doi.org/10.1038/s41591-024-03037-z

Waterfall plot for CT041 (CLDN18.2 CAR-T)

242

Reposted by Tumor Board Tuesday

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

19/31 #TumorBoardTuesday Mini Tutorial 16 4) Phase 1/2, PM1032 (CLDN18.2 x 41BB bispecific) in adv solid tumors (NCT05839106) Activates T and NK cells 30 patients, no DLTs, 66.7% CLDN18.2+ 14 gastric/GEJ, 10 panc, 5 other GI 17 CLDN18.2+ pts at ≥5 mg/kg: 2 PR, 7 SD

PM1032 (bispecific targeting CLDN18.2 and 41BB) in advanced solid tumors

142

Reposted by Tumor Board Tuesday

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

18/31 #TumorBoardTuesday 🏫Mini Tutorial 15🏫 Efficacy for 600 µg/kg in CLDN18.2 IHC 2+/3+ ≥10%: 27 pts, 8 PRs, 11 SDs, ORR 39.6%, DCR 70.4% DOR and PFS not reached

242

Reposted by Tumor Board Tuesday

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

15/31 #TumorBoardTuesday 🏫Mini Tutorial 12🏫 CLDN18.2 bispecific trials: 1) Phase 1, Q-1802 (PD-L1 x CLDN18.2) (NCT04856150) 17 pts w/ adv gastric, PC, or BTC, mostly ≥3 prior lines 2/9 PRs, 4/9 SDs AEs: n/v, abd pain, GERD 24.1% G3 TRAEs doi.org/10.1200/JCO.2023.41.4_suppl.382

252

Reposted by Tumor Board Tuesday

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

16/31 #TumorBoardTuesday 🏫Mini Tutorial 13🏫 2) Phase 1, ASP2138 (CD3 x CLDN18.2 BiTE) ± chemo in CLDN18.2+ adv gastric/GEJ or PC (NCT05365581) 2+1: 2 CLDN18.2 binding sites, 1 CD3 binding site

243

Reposted by Tumor Board Tuesday

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

17/31 #TumorBoardTuesday 🏫Mini Tutorial 14🏫 3) Phase 1, IBI389 (CLDN18.2 x CD3) in adv PDAC (NCT05164458) 64 patients, median 2 prior lines 54.7% G3+ TRAEs: GGT increased, lymphs decreased, nausea 51.6% CRS, no grade 3+ TEAEs -> dose interruption 37.5%, discontinuation 4.7%

143

Reposted by Tumor Board Tuesday

Mike Pishvaian @mpishvaian.bsky.social · 05/02/2025

#TumorBoardTuesday Wow - that was worth the anticipation This is as a single agent (ADC)❓ This is as promising as all the (well deserved) hype with KRAS⛔

media.tenor.com

a man in a suit and tie is sitting at a desk and says " yes please "

ALT: a man in a suit and tie is sitting at a desk and says " yes please "

011

Reposted by Tumor Board Tuesday

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

14/31 #TumorBoardTuesday 🏫Mini Tutorial 11🏫 CLDN18.2 IHC 1+/2+/3+ ≥40%: ORR 28% (all PRs: 5 PDAC, 2 BTC), DCR 80% CLDN18.2 ≥60%: ORR 38.5% (all PRs: 4 PDAC, 1 BTC), DCR 84.6% 25.7% G3+ TRAEs: anemia, neutropenia, elevated AST Dose interruption 20%, discontinuation 2.9%

233

Reposted by Tumor Board Tuesday

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

13/31 #TumorBoardTuesday 🏫Mini Tutorial 10🏫 2) Phase 1, IBI343 (CLDN18.2 ADC w/ exatecan) in PDAC or BTC (NCT05458219) 35 patients enrolled: 28 PDAC, 7 BTC (all pretreated) Dose expansion: CLDN18.2 IHC 1+/2+/3+ ≥40% doi.org/10.1200/JCO.2024.42.16_suppl.3037

243

Reposted by Tumor Board Tuesday

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

12/31 #TumorBoardTuesday Mini Tutorial 9 Trials of CLDN18.2 ADCs: 1) Phase 1, SYSA1802/EO3021 (CLDN18.2 ADC w/ MMAE) in adv solid tumors (NCT05980416) Promising results in gastric/GEJ, panc results pending TEAEs: nausea, anorexia, fatigue, diarrhea

142

Reposted by Tumor Board Tuesday

Mike Pishvaian @mpishvaian.bsky.social · 05/02/2025

#TumorBoardTuesday So - it seems like there is higher Claudin 18.2 expression in more advanced #PancreaticCancer - but interesting that its expression is not associated with survival🤔

011

Reposted by Tumor Board Tuesday

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

11/31 #TumorBoardTuesday 🏫Mini Tutorial 8🏫 2) Phase 1b, 1L FG-M108 + gem/abraxane for advPC w/ CLDN18.2 IHC 1+/2+/3+ ≥10% (NCT04894825) FG-M108: afucosylated human CLDN18.2 mAb w/ enhanced ADCC ORR 50%, DCR 100% among 14 pts SEs: nausea, emesis, neutropenia, anemia

FG-M108 plus nab-paclitaxel and gemcitabine 1L for CLDN18.2+ locally advanced unresectable or metastatic pancreatic cancer

243

Reposted by Tumor Board Tuesday

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

10/31 #TumorBoardTuesday 🏫Mini Tutorial 7🏫 Trials of CLDN18.2 antibodies: 1) Phase 2, mPC w/ mod-strong CLDN18.2 IHC >75% randomized to 1L gem/abraxane ± zolbetuximab (NCT03816163) - results pending (rb.gy/yhczya)

132

Reposted by Tumor Board Tuesday

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

9/31 #TumorBoardTuesday 🏫Mini Tutorial 6🏫 CLDN18.1 isoform is expressed in lung CLDN18.2 is dominant in gastric/pancreatic cancer (rb.gy/uwykch) % CLDN18.2+ seems to matter more than staining intensity (unlike HER2)

142

Reposted by Tumor Board Tuesday

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

8/31 #TumorBoardTuesday 🏫Mini Tutorial 5🏫 Ventana CLDN18 43-14A RxDx assay FDA approved for zolbetuximab in gastric/GEJ adeno 43-14A binds intracellular domain, does not distinguish CLDN18.2 vs CLDN18.1 doi.org/10.1038/s41571-024-00874-2

Binding sites of anti-CLDN18.2 antibodies

132

Reposted by Tumor Board Tuesday

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

7/31 #TumorBoardTuesday 🏫Mini Tutorial 4🏫 More CLDN18.2+ if N+ (64% vs 40%) or M1 (79% vs 44%) CLDN18.2 not associated w/ survival (doi.org/10.4251/wjgo.v14.i7.1252) LN and liver mets also express CLDN18.2 (>60%) (doi.org/10.1002/ijc.28400)

232

Reposted by Tumor Board Tuesday

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

6/31 #TumorBoardTuesday 🏫Mini Tutorial 3🏫 Transcription regulated by PKC signaling and CpG methylation Higher CLDN18.2 in gastric-type IPMN (vs intestinal-type), well-diff PDAC (vs poor-diff) doi.org/10.1002/jcb.23095

242

Reposted by Tumor Board Tuesday

Mike Pishvaian @mpishvaian.bsky.social · 05/02/2025

#TumorBoardTeusday I could definitely see trying FOLFIRINOX or some permutation again 🤔Any NGS🧬results❓

021

Reposted by Tumor Board Tuesday

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

🏫Mini Tutorial 1🏫 CLDN18.2 In normal gastric mucosa: part of tight junctions, not accessible In gastric cancer: becomes exposed -> targetable doi.org/10.1038/s41571-024-00874-2

CLDN18.2 in nonmalignant cells vs. in cancer cells

232

Reposted by Tumor Board Tuesday

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

5/31 #TumorBoardTuesday 🏫Mini Tutorial 2🏫 CLDN18.2 ectopically expressed in PanIN (97%), IPMNs (95), MCNs (80%), PDAC (70%), but not normal pancreatic duct (doi.org/10.1369/0022155411420569)

CLDN18.2 IHC in normal pancreas, PanIN, IPMN, and PDAC

242

Reposted by Tumor Board Tuesday

Mike Pishvaian @mpishvaian.bsky.social · 05/02/2025

#TumorBoardTuesday Waiting for a RAS⛔trial is definitely the most common answer (and probably the right one) 📣When are we going to get rapid espanded access to these new agents 👉Calling on you @fda.gov

011

Reposted by Tumor Board Tuesday

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

3/31 #TumorBoardTuesday Continued gem/abraxane Waitlisted for RAS inhibitor trials Screened for CLDN18.2 x CD3 bispecific trial

243

Reposted by Tumor Board Tuesday

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

2/31 #TumorBoardTuesday Abd wall met bx: panc adenocarcinoma MSS TMB 8.5 mut/Mb KRAS G12R CDKN2A frameshift mutation TP53 R282W BRCA1/2 wild-type CLDN18.2 1–50% (positive, low)

143

Reposted by Tumor Board Tuesday

Katherine Zhou @katherinezhoumd.bsky.social · 05/02/2025

1/31 #TumorBoardTuesday 73yo M w/ PDAC met to abd wall, R pelvis, and b/l inguinal canals S/p Whipple + 6 mos adj FOLFIRINOX 3 yrs ago for T2N1 disease 1L gem/abraxane -> PD after 4 mos w/ slight growth of abd wall met (2.8 -> 3.2 cm) ECOG PS 1

244

Reposted by Tumor Board Tuesday

Mike Pishvaian @mpishvaian.bsky.social · 04/02/2025

✅This #TumorBoardTuesday🗣️with @ndevitomd.bsky.social & @katherinezhoumd.bsky.social is provided by @IntegrityCE 👍Supported by ed grants from Astellas, AstraZeneca, Janssen, Lilly, Novartis, Seagen and Taiho Oncology🙏 Info about 🆓 CME: integrityce.com/TBT2024

122

Reposted by Tumor Board Tuesday

Mike Pishvaian @mpishvaian.bsky.social · 04/02/2025

#PreTest Q1️⃣ #TumorBoardTuesday Free #CME integrityce.com/TBT2024 B4⃣@ndevitomd.bsky.social & @katherinezhoumd.bsky.social🗣️Claudin 18.2 as a🎯in #pancreaticcancer , test your🧠with these 2❓ 🤔What % of pancreatic adenocarcinoma cases typically express Claudin 18.2❓ 1) 30% 2) 50% 3) 70% 4) 90%

131

Reposted by Tumor Board Tuesday

Mike Pishvaian @mpishvaian.bsky.social · 04/02/2025

#PreTest Q2⃣#TumorBoardTuesday Free #CME integrityce.com/TBT2024 🧐 Which of the following would you select for a 78-year-old man with mPDAC (CLDN18.2, 45%; MSS; gBRCA WT) and disease progression after gemcitabine/nab=pac❓ 1) FOLFIRINOX 2) Regorafenib trial 3) CLDN18.2 BiTe trial 4) Pembrolizumab

141

Tumor Board Tuesday @tumorboardtuesday.bsky.social · 03/02/2025

#TumorBoardTuesday 🤔Can Claudin 18.2 be used for treatment💊outside of upper GI cancers❓ 📢Join us Tuesday, 02-04-25 at 8PM ET as @ndevitomd.bsky.social & @katherinezhoumd.bsky.social from @dukemedschool.bsky.social 🗣️Claudin 18.2 as a🎯in #pancreaticcancer RT and bring others into the discussion‼️

153

Reposted by Tumor Board Tuesday

Xiaojie (Zoe) Zhang @zoezhang.bsky.social · 15/01/2025

18/20 #TumorBoardTuesday @dr-rshatsky.bsky.social Beyond SERDs/SERMs…novel endocrine therapies targeting other mechanisms in pipeline: Proteolysis targeting chimeras (PROTACs), selective ER covalent antagonists, complete ER antagonists just to name a few!🤯

453

Reposted by Tumor Board Tuesday

Xiaojie (Zoe) Zhang @zoezhang.bsky.social · 15/01/2025

20/20 #TumorBoardTuesday @dr-rshatsky.bsky.social 🔑points 👉Novel ET are changing trt landscape for ER+/HER2- ABC 🤔W/ expanding options, come opportunities and challenges ➡️Many burning questions: Sequencing therapy, new combinations (ie CDK4/6i+SERDs)...

media.tenor.com

a little girl is crying and holding her fist in the air with the word exciting written on the bottom .

ALT: a little girl is crying and holding her fist in the air with the word exciting written on the bottom .

342

Reposted by Tumor Board Tuesday

Xiaojie (Zoe) Zhang @zoezhang.bsky.social · 15/01/2025

#PostTest Q1️⃣ #TumorBoardTuesday 👉🏽#CME Eval 🔗 integrityce.com/TBTeval24 👉🏽ALL CME🔗 integrityce.com/TBT2024 Per INAVO120 data in ET-refractory, PIK3CA+ HR+ la/mBC, adding inavolisib to palbociclib + fulvestrant improved mPFS to: 9 months 12 months 15 months 18 months

integrityce.com

2024 Tumor Board Tuesday Evaluation

Take this survey powered by surveymonkey.com. Create your own surveys for free.

132

Reposted by Tumor Board Tuesday

Xiaojie (Zoe) Zhang @zoezhang.bsky.social · 15/01/2025

#PostTest Q2️⃣ #TumorBoardTuesday 👉🏽 Free CME 🔗 integrityce.com/TBT2024 Which is likely to be optimal for HR+ mBC that progresses after 1Y of 1L ribociclib + AI and harbors an ESR1 Y537S mutation? Abemaciclib + fulvestrant Imlunestrant + abemaciclib Elacestrant Capivasertib + fulvestrant

integrityce.com

Tumor Board Tuesday 2024 - Integrity CE

Tumor Board Tuesdays is a regularly scheduled, Twitter-based case discussion forum led by expert faculty exploring cases in various solid tumor malignancies. The series will focus on practice applicat...

032

Reposted by Tumor Board Tuesday

Dr. RShatsky @dr-rshatsky.bsky.social · 15/01/2025

I love this so much! I want to be in a place where I have TOO MANY options for my patients and struggle to choose. It’s never been that way and I am really feeling hopeful that we’re getting there. Because #StageIVNeedsMore! #CanSky #OncSky @tumorboardtuesday.bsky.social

051

Reposted by Tumor Board Tuesday

Xiaojie (Zoe) Zhang @zoezhang.bsky.social · 15/01/2025

11/20 #TumorBoardTuesday @dr-rshatsky.bsky.social 👩‍⚕️Mini Tutorial 2👩‍⚕️ ESR1 mutations are present in: ~4% of 1L setting ~30% in 2L+ setting 👉Not all ESR1 mutations are created the same! -ESR1 Y537S is associated with relative resistance to fulvestrant! pmc.ncbi.nlm.nih.gov/articles/PMC...

243

Reposted by Tumor Board Tuesday

Xiaojie (Zoe) Zhang @zoezhang.bsky.social · 15/01/2025

12/20 #TumorBoardTuesday @dr-rshatsky.bsky.social 2023, FDA approved elacestrant based on the EMERALD trial Pts: prior 1-2L ET, ≤1 chemo for ABC: R 1:1 ➡️elacestrant vs SoC ➡️ PFS all: HR = 0.70; p = .002 PFS ESR1m: HR = 0.55; p = .0005 Benefit in key subgroups: PIK3CA mut, ESR1 mut, and TP53 mut

153

Reposted by Tumor Board Tuesday

Xiaojie (Zoe) Zhang @zoezhang.bsky.social · 15/01/2025

13/20 #TumorBoardTuesday @dr-rshatsky.bsky.social 👩‍⚕️Mini Tutorial 4👩‍⚕️ Novel, oral SERDs in development w/ ⬆️efficacy ⬇️toxicities 👉💡imlunestrant, studied in the EMBER-3 trial presented at #SABCS24 🔑Pt features: ~37% with ESR1m, ~40% with PIK3CAm, >50% visceral disease 👉1/3 adj ET, 2/3 prior CDK4/6i

364